The patent covers pharmaceutical compositions of a DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos or ZIO-201) and their use in treating cancer.
The company has also received Australian patent covering a crystalline form of darinaparsin (Zinapar or ZIO-101), pharmaceutical compositions containing such compounds, and methods to use in cancer treatment.
ZIOPHARM chief legal officer Caesar Belbel said that both the allowance and recent issuance are evidence of their continued execution of global development programs.